ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Gastrointestinal and Hepatic Pharmacology
Glial cell line-derived neurotrophic factor inhibits mast-cell-like RBL-2H3 cells activation via Ca2+-mediated degranulation and Ca2+/CaMK Ⅱ/JNK pathway
Provisionally accepted- Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Abstract Introduction: Mast cells are important component of the intestinal immune system, play a crucial role in the pathogenesis of IBD. Glial cell line-derived neurotrophic factor (GDNF), as a multifunctional growth factor, has recently garnered attention for its role in the inhibition of mast cells activation. This study aims to explore the the potential mechanisms by which GDNF inhibits mast cell activation. Methods: In this study, RBL-2H3 cells were used as an in vitro cell model of mast cells, which were cultured and treated with various interventions prior to collection of cells and culture supernatants. IgE-mediated degranulation were evaluated through β -hexosaminidase release assays. Culture supernatants were analyzed for TNFα, IL-1β, and IL-6 secretion using ELISA. Key signaling molecules—GDNF family receptor α1(GFRα1), receptor Tyrosine Kinase(RET), calcium/calmodulin-dependent protein kinase II (CaMKⅡ), total and phosphorylated c-Jun N-terminal kinase (JNK), and JNK isoforms—were quantified at mRNA and protein levels using Quantitative Real-time PCR(qRT-PCR) and Western blot. Intracellular Ca²⁺ were monitored fluorometrically. Immunofluorescence and protein binding assays were used to confirm interactions between GDNF-GFRα1/RET complexes and CaMKⅡ-JNK associations. Results: GDNF inhibited the degranulation and release of inflammatory cytokines in activated RBL-2H3 cells. The intracellular Ca2+ and the phosphorylation of JNK were reduced in activated RBL-2H3 cells after GDNF treatment. Immunofluorescence results demonstrated co-localization of GDNF with GFRα1 on RBL-2H3 cell membranes and CaMKII with JNK in the cytoplasm. There were interactions between GDNF and GFRα1/RET, as well as CaMK II and JNK. RET inhibitor eliminated this inhibitory effect of GDNF on RBL-2H3 cell degranulation and inflammatory factor release. Ca2+ chelator and CaMKⅡRNAi had the same inhibitory effect on degranulation, release of inflammatory cytokines and phosphorylation of JNK. However, in their presence, GDNF had no additional inhibitory effect. Conclusions: GDNF can decrease the intracellular concentration of Ca²⁺ in activated RBL-2H3 cells by attaching to GFLα1/RET receptors located on the membrane of RBL-2H3 cells, subsequently inhibiting Ca²⁺-mediated degranulation and the Ca²⁺/CaMKII/JNK pathway responsible for the release of inflammatory cytokines.
Keywords: Glial cell line-derived neurotrophic factor (GDNF), Mast cell (MC), Ca2+, inflammatory bowel disease, C-Jun N-terminal kinase (JNK)
Received: 02 Sep 2025; Accepted: 07 Nov 2025.
Copyright: © 2025 Huang, Zeng, Zhang, Zhang and Xie. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Qin Xie, qinqin688418@126.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
